{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:16:25Z","timestamp":1777389385098,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000262","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022974","name":"Global Alliance for Chronic Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000241","name":"Physicians' Services Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcjo.2025.05.021","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:15:19Z","timestamp":1750662919000},"page":"321-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A real-world population-based study on the association between cataracts and antipsychotics"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4603-826X","authenticated-orcid":false,"given":"Moiz","family":"Lakhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-1112","authenticated-orcid":false,"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-0027","authenticated-orcid":false,"given":"Emaan","family":"Chaudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5014-561X","authenticated-orcid":false,"given":"Jim Shenchu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-6014","authenticated-orcid":false,"given":"Amrit S.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandeep S.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2025.05.021_bib0001","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ajo.2023.01.005","article-title":"Evaluation of systemic medications associated with surgically treated cataract among US adults","volume":"249","author":"Deng","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0002","first-page":"751","article-title":"Global prevalence and causes of visual impairment with special reference to the general population of Saudi Arabia","volume":"34","author":"Alswailmi","year":"2018","journal-title":"Pak J Med Sci Q"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0003","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1038\/s41433-024-02961-1","article-title":"Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020","volume":"38","author":"Pesudovs","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0004","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0005","doi-asserted-by":"crossref","first-page":"e1744","DOI":"10.1016\/S2214-109X(22)00419-3","article-title":"Effective cataract surgical coverage in adults aged 50 years and older: estimates from population-based surveys in 55 countries","volume":"10","author":"McCormick","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.947659","article-title":"Drugs associated with cataract formation represent an unmet need in cataract research","volume":"9","author":"Carlson","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-018-0699-0","article-title":"Antidepressants use and risk of cataract development: a systematic review and meta-analysis","volume":"18","author":"Fu","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0008","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jamaophthalmol.2013.4575","article-title":"Association of statin use with cataracts: a propensity score-matched analysis","volume":"131","author":"Leuschen","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0009","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.eye.6701964","article-title":"External factors in the development of cataract","volume":"19","author":"Robman","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0010","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajo.2004.05.038","article-title":"Twice-yearly exams unnecessary for patients taking quetiapine","volume":"138","author":"Fraunfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0011","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.schres.2019.07.049","article-title":"Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: a retrospective cohort study","volume":"212","author":"Fang","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2016.11.019","article-title":"Association between antipsychotic drug use and cataracts in patients with bipolar disorder: a population-based, nested case-control study","volume":"209","author":"Chu","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0013","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.schres.2016.03.027","article-title":"Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: a population-based, nested case-control study","volume":"174","author":"Chou","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0014","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19f12744","article-title":"Antidepressants, mood stabilizers, antipsychotics, and the risk of cataract","volume":"80","author":"Andrade","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2165\/11533180-000000000-00000","article-title":"Ocular adverse effects of common psychotropic agents: a review","volume":"24","author":"Richa","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0016","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","article-title":"Side effects of atypical antipsychotics: a brief overview","volume":"7","author":"U\u00e7ok","year":"2008","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0017","first-page":"e2553","article-title":"Olanzapine-induced cataract in a teenage girl","volume":"10","author":"Lim","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0018","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1176\/appi.psy.43.5.354","article-title":"Cataract occurrence with antipsychotic drugs","volume":"43","author":"Shahzad","year":"2002","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0019","first-page":"413","article-title":"Experimental chlorpromazine cataracts","volume":"8","author":"Howard","year":"1969","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/archopht.1991.01080020102053","article-title":"Exposure to phenothiazine drugs and risk of cataract","volume":"109","author":"Isaac","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0021","unstructured":"U.S. Food and Drug Administration. U.S. Food and Drug Administration. July 8, 2024. Accessed July 9, 2024. https:\/\/www.fda.gov\/"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0022","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic drug\u2013related weight gain and its treatment","volume":"181","author":"McIntyre","year":"2024","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0023","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2415-14-94","article-title":"Meta-analysis of the risk of cataract in type 2 diabetes","volume":"14","author":"Li","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0024","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S1092852922001043","article-title":"The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia","volume":"28","author":"Jawad","year":"2023","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41598-023-50582-7","article-title":"Association between cataract and fatty liver diseases from a nationwide cross-sectional study in South Korea","volume":"14","author":"Kang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0026","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1167\/iovs.10-6373","article-title":"Metabolic syndrome components and age-related cataract: the Singapore Malay eye study","volume":"52","author":"Sabanayagam","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0027","first-page":"804","article-title":"Association between metabolic syndrome and age-related cataract","volume":"8","author":"Park","year":"2015","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0028","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/nu14091684","article-title":"Metabolic syndrome is associated with cataract in a large Taiwanese population study","volume":"14","author":"Chang","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0029","series-title":"Research. FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S","year":"2023"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0030","unstructured":"OpenVigil 2.1-MedDRA. Accessed June 27, 2024. http:\/\/h2876314.stratoserver.net:8080\/OV2\/search\/"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0031","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil\u2014free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0032","unstructured":"FDA Surveillance Programs. Toolkit. November 18, 2020. Accessed January 8, 2025. https:\/\/toolkit.ncats.nih.gov\/module\/after-fda-approval\/after-fda-approval\/fda-surveillance-programs\/"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008\u201319: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0034","unstructured":"MedWatch Online Voluntary Reporting Form. Accessed April 22, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/medwatch\/index.cfm"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0035","unstructured":"MedWatch Online Voluntary Reporting Form. Accessed April 22, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/medwatch\/index.cfm"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0036","unstructured":"MedWatch Online Voluntary Reporting Form. Accessed April 22, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/medwatch\/index.cfm"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0037","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and non-arteritic anterior ischemic optic neuropathy: a multinational population-based real-world study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0038","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0039","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0041","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0042","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bjpt.2018.12.006","article-title":"Understanding and interpreting confidence and credible intervals around effect estimates","volume":"23","author":"Hespanhol","year":"2019","journal-title":"Braz J Phys Ther"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0043","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajo.2025.03.023","article-title":"Drugs associated with floppy Iris syndrome: a real-world population-based study","volume":"275","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14740338.2025.2460454","article-title":"Association of ocular adverse events with varenicline solution use: a population-based study","volume":"24","author":"Lakhani","year":"2025","journal-title":"Opin Drug Saf"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0044","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0045","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0161-6420(98)99049-2","article-title":"Medications and cataract. The Blue Mountains Eye Study","volume":"105","author":"Cumming","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0046","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0161-6420(99)00029-9","article-title":"Schizophrenia, psychotropic medication, and cataract","volume":"107","author":"Gaynes","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0047","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0253-7176.70546","article-title":"Chlorpromazine induced cataract in a young patient with schizophrenia","volume":"32","author":"Divakaran","year":"2010","journal-title":"Indian J Psychol Med"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0048","unstructured":"AstraZeneca Canada. Accessed July 18, 2024. https:\/\/www.astrazeneca.ca\/en\/"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0049","unstructured":"U.S. Food and Drug Administration. U.S. Food and Drug Administration. July 15, 2024. Accessed July 18, 2024. https:\/\/www.fda.gov\/"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3126\/jpan.v11i2.57688","article-title":"Chlorpromazine induced cataract in a female patient: a case report","volume":"11","author":"Thapa","year":"2022","journal-title":"J Psychiatr Assoc Nepal"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0051","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0052","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/wps.20997","article-title":"The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management","volume":"21","author":"McIntyre","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0053","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v69n0401","article-title":"Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges","volume":"69","author":"Fleischhacker","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0054","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24com15322","article-title":"The co-occurrence of depression and obesity: implications for clinical practice and the discovery of targeted and precise mechanistically informed therapeutics","volume":"85","author":"McIntyre","year":"2024","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2024-301021","article-title":"Comorbid physical health burden of serious mental health disorders in 32 European countries","volume":"27","author":"Wienand","year":"2024","journal-title":"BMJ Ment Health"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0056","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.4103\/ijo.IJO_2101_22","article-title":"Psychiatric aspects of ophthalmic disorders: A narrative review","volume":"71","author":"Mamtani","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286860","article-title":"Severe mental illness and ophthalmic health: A linked administrative data study","volume":"18","author":"Ferry","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0058","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.2147\/OPTH.S258783","article-title":"Visual impairment and mental health: unmet needs and treatment options","volume":"14","author":"Demmin","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0059","article-title":"The prevalence of depression and depressive symptoms among eye disease patients: a systematic review and meta-analysis","volume":"7","author":"Zheng","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jad.2021.12.110","article-title":"Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis","volume":"300","author":"Liu","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0061","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1444-0938.2002.tb03011.x","article-title":"What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts","volume":"85","author":"Jobling","year":"2002","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0062","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.survophthal.2006.12.003","article-title":"Obesity and eye diseases","volume":"52","author":"Cheung","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0063","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/OPX.0000000000000243","article-title":"Overweight, obesity, and age-related cataract: a meta-analysis","volume":"91","author":"Pan","year":"2014","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0064","series-title":"How smoking can contribute to vision loss and blindness","year":"2023"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1566524016666160126144601","article-title":"The adverse effects of smoking on health outcomes in bipolar disorder: a review and synthesis of biological mechanisms","volume":"16","author":"Slyepchenko","year":"2016","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0066","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/wps.20332","article-title":"Smoking cessation should be an integral part of serious mental illness treatment","volume":"15","author":"Schroeder","year":"2016","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0067","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaophthalmol.2013.6669","article-title":"Smoking cessation and the risk of cataract: a prospective cohort study of cataract extraction among men","volume":"132","author":"Lindblad","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0068","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1248\/bpb.17.237","article-title":"The relationship between properties of antipsychotic drugs and cataract formation","volume":"17","author":"Kamei","year":"1994","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0069","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.molmed.2012.03.005","article-title":"Protein misfolding and aggregation in cataract disease and prospects for prevention","volume":"18","author":"Moreau","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jad.2017.03.044","article-title":"Antidepressants and risk of cataract development: a population-based, nested case-control study","volume":"215","author":"Chou","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jcjo.2025.05.021_bib0071","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jad.2017.10.017","article-title":"Associations between use of mood stabilizers and risk of cataract: a population-based nested case-control study","volume":"227","author":"Chu","year":"2018","journal-title":"J Affect Disord"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225002662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225002662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T22:38:41Z","timestamp":1764628721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418225002662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0008418225002662"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.05.021","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world population-based study on the association between cataracts and antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}